SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma models

Cellular Physiology and Biochemistry

Volumn 32, Issue 1, 2013, Pages 138-153

  Chen, Xin ^a   Ji, Pan ^a   Yang, Hui Wen ^a   Yang, Ling Ling ^a   Zhou, Shu ^a   Zhong, Lei ^a   Ma, Shuang ^a   Fu, Xiao Yu ^a   Zhou, Chan ^a   Li, Guo Bo ^a   Zheng, Ming Wu ^a   Wei, Yu Quan ^a   Yang, Sheng Yong ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Antiangiogenesis; BRAF; CRAF; G2 M phase cell cycle arrest; SC 535

Indexed keywords

ANTINEOPLASTIC ALKALOID; SC 535; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; B RAF KINASE; PHOSPHOTRANSFERASE INHIBITOR; RAF PROTEIN; SORAFENIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ASSAY; CELL GROWTH; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; EMBRYO; FEMALE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING; ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER SIZE; CUTANEOUS MELANOMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MELANOMA CELL; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION;

MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; G2 PHASE CELL CYCLE CHECKPOINTS; HALF-LIFE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MALE; MELANOMA; MICE; MICE, NUDE; NEOVASCULARIZATION, PHYSIOLOGIC; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; PYRAZOLES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; ZEBRAFISH;

EID: 84880184008     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000350123     Document Type: Article

References (47)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 2012.
2. Miller AJ, Mihm MC: Mechanisms of disease melanoma. N Engl J Med 2006;355:51-65.
3. Flaherty KT, Hodi FS, Fisher DE: From genes to drugs: Targeted strategies for melanoma. Nat rev Cancer 2012;12:349-361.
4. Chang L, Karin M: Mammalian map kinase signalling cascades. Nature 2001;410:37-40.
5. Dhillon AS, Hagan S, Rath O, Kolch W: Map kinase signalling pathways in cancer. Oncogene 2007;26:3279-3290.
6. Davies H, Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Stratton MR, Futreal PA: Mutations of the braf gene in human cancer. Nature 2002;417:949-954.
7. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, Gogineni A, Zha J, Cole MJ, Stern HM, Murray LJ, Davis DP, Seshagiri S: Oncogenic braf is required for tumor growth and maintenance in melanoma models. Cancer Res 2006;66:999-1006.
8. Kolch W, Kotwaliwale A, Vass K, Janosch P: The role of raf kinases in malignant transformation. Expert Rev Mol Med 2002;4:1-18.
9. Bastian B, Lo R, Ribas A: Society for melanoma research 2012 congress. Pigment Cell Melanoma Res 2012;25:836-903.
10. Claffey KP, Brown LF, del Aguila LF, Tognazzi K, Yeo KT, Manseau EJ, Dvorak HF: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996;56:172-181.
11. Pralhad T, Madhusudan S, Rajendrakumar K: Concept, mechanisms and therapeutics of angiogenesis in cancer and other diseases. J Pharm Pharmacol 2003;55:1045-1053.
12. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat rev Cancer 2003;3:401-410.
13. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
14. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase iii randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
15. Mangana J, Levesque MP, Karpova MB, Dummer R: Sorafenib in melanoma. Expert Opin Investig Drugs 2012;21:557-568.
16. Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nat-hanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ: Sorafenib in advanced melanoma: A phase ii randomised discontinuation trial analysis. Br J Cancer 2006;95:581-586.
17. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: A multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844.
18. Fruehauf J, Lutzky J, McDermott D, Brown CK, Meric JB, Rosbrook B, Shalinsky DR, Liau KF, Niethammer AG, Kim S, Rixe O: Multicenter, phase ii study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011;17:7462-7469.
19. Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M: Multi-kinase inhibitor e7080 suppresses lymph node and lung metastases of human mammary breast tumor mda-mb-231 via inhibition of vascular endothelial growth factor-receptor (vegf-r) 2 and vegf-r3 kinase. Clin Cancer Res 2008;14:5459-5465.
20. Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C: Erlotinib and bevacizumab have synergistic activity against melanoma. Clin Cancer Res 2009;15:3495-3502.
21. Garcia-Gomez A, Ocio EM, Pandiella A, San Miguel JF, Garayoa M: Raf265, a dual braf and vegfr2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs 2013;31:200-205.
22. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY: Structure -activity relationship studies of pyrazolo[3,4-d ]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits flt3 and vegfr2 and valuation of its activity against acute myeloid leukemia in vitro and in vivo. J Med Chem 2013;56:1641-1655.
23. Lewis LJ, Hoak JC, Maca RD, Fry GL: Replication of human endothelial cells in culture. Science 1973;181:453-454.
24. Heo DS, Park JG, Hata K, Day RM, Herberman RB, Whiteside TL: Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res 1990;50:3681-3690.
25. Cappella P, Gasparri F, Pulici M, Moll J: A novel method based on click chemistry, which overcomes limitations of cell cycle analysis by classical determination of brdu incorporation, allowing multiplex antibody staining. Cytometry A 2008;73:626-636.
26. Dai XY, Zeng XX, Peng F, Han YY, Lin HJ, Xu YZ, Zhou T, Xie G, Deng Y, Mao YQ, Yu LT, Yang L, Zhao YL: A novel anticancer agent, sklb70359, inhibits human hepatic carcinoma cells proliferation via g0/g1 cell cycle arrest and apoptosis induction. Cell Physiol Biochem 2012;29:281-290.
27. Pan YL, Xu Y, Feng S, Luo SD, Zheng RL, Yang J, Wang LJ, Zhong L, Yang HY, Wang BL, Yu Y, Liu JJ, Cao ZX, Wang XY, Ji P, Wang ZR, Chen X, Zhang S, Wei YQ, Yang SY: Sklbl206, a novel orally available multikinase inhibitor targeting egfr activating and t790m mutants, erbb2, erbb4, and vegfr2, displays potent antitumor activity both in vitro and in vivo. Mol Cancer Ther 2012;11:952-962.
28. Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL: Sklb6l0: A novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. Cell Physiol Biochem 2011;27:565-574.
29. Hoffmann J, Schirner M, Menrad A, Schneider MR: A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate- encapsulated tumor cells. Cancer Res 1997;57:3847-3851.
30. Zhang S, Cao ZX, Tian HW, Shen GB, Ma YP, Xie HZ, Liu YL, Zhao CJ, Deng SY, Yang Y, Zheng RL, Li WW, Zhang N, Liu SY, Wang W, Dai L, Shi S, Cheng L, Pan YL, Feng S, Zhao X, Deng HX, Yang SY, Wei YQ: Sklbl002, a novel potent inhibitor of vegf receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Clin Cancer Res 2011;17:4439-4450.
31. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Sim-cox ME, Heimbrook D, Bollag G, Su F: Rg7204 (plx4032), a selective brafv600e inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70:5518-5527.
32. Villanueva J, Vultur A, Herlyn M: Resistance to braf inhibitors: Unraveling mechanisms and future treatment options. Cancer Res 2011:7137-7140.
33. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, DAndrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K: Clinical efficacy of a raf inhibitor needs broad target blockade in braf mutant melanoma. Nature 2010;467:596-599.
34. McMahon G: Vegf receptor signaling in tumor angiogenesis. Oncologist 2000;5:3-10.
35. Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler EK, Stoeltzing O, Lang SA: Targeting fgfr/pdgfr/vegfr impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 2011;10:2157-2167.
36. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Vozne-sensky A, Riedl B, Post LE, Bollag G, Trail PA: Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the raf/mek/erk pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
37. Dhomen N, Marais R: New insight into braf mutations in cancer. Curr Opin Genet Dev 2007;17:31-39.
38. Amaravadi RK, Schuchter LM, McDermott DF, Kramer A, Giles L, Gramlich K, Carberry M, Troxel AB, Letrero R, Nathanson KL, Atkins MB, O'Dwyer PJ, Flaherty KT: Phase ii trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009;15:7711-7718.
39. Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK: Randomized phase ii trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (s0438). Clin Cancer Res 2012;18:1129-1137.
40. Kaempgen E, Schmid M, Erdmann M, Keikavoussi P, Strobel D, Schuler-Thurner B, Schuler G: Predictable clinical responses to sorafenib in stage iv uveal melanoma. J Clin Oncol Abstr 2012;30.
41. Panka DJ, Wang W, Atkins MB, Mier JW: The raf inhibitor bay 43-9006 (sorafenib) induces caspase-inde-pendent apoptosis in melanoma cells. Cancer Res 2006;66:1611-1619.
42. Wang R, He G, Nelman-Gonzalez M, Ashorn CL, Gallick GE, Stukenberg PT, Kirschner MW, Kuang J: Regulation of cdc25c by erk-map kinases during the g2/m transition. Cell 2007;128:1119-1132.
43. Samadi AK, Zhang X, Mukerji R, Donnelly AC, Blagg BS, Cohen MS: A novel c-terminal hsp90 inhibitor ku135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer letters 2011;312:158-167.
44. Arozarena I, Sanchez-Laorden B, Packer L, Hidalgo-Carcedo C, Hayward R, Viros A, Sahai E, Marais R: Oncogenic braf induces melanoma cell invasion by downregulatingthe cgmp-specific phosphodiesterase pde5a. Cancer Cell 2011;19:45-57.
45. Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Mer-ghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N: Relief of profound feedback inhibition of mitogenic signaling by raf inhibitors attenuates their activity in brafv600e melanomas. Cancer Cell 2012;22:668-682.
46. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J: Elevated craf as a potential mechanism of acquired resistance to braf inhibition in melanoma. Cancer Res 2008;68:4853-4861.
47. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK: Regulation of raf-1 by direct feedback phosphorylation. Mol Cell 2005;17:215-224.